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Summary
In chronic cardiomyopathy, mechanical circulatory support
plays an increasingly important role for children as the
shortage of suitable donor hearts increases times on the
transplant waiting list. Ventricular assist devices (VADs)
for adults have evolved dramatically over the last decade,
both as a bridge to transplantation and for permanent sup-
port. In contrast, VADs designed for children, especially
for all age groups, are still in their infancy. The Medos HIA
and the Berlin Heart Excor are specially designed for chil-
dren with a body surface area <1.2 m2. Increased exper-
ience with existing paediatric VADs and the introduction
of third-generation VADs for the paediatric age group of-
fer new possibilities for children suffering from end-stage
heart failure. We review the literature on this topic, sum-
marise the indications and contraindications for long-term
support VADs and describe the decision-making algorithm
used at our institution for use of long-term VADs in chil-
dren.
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Background
Hospitalisation of children suffering from heart failure due
to congenital heart disease is increasing [1] and heart trans-
plantation (HTx) remains the treatment of choice although
it is limited by the shortage of suitable organ donors.
Various initiatives have been introduced to overcome donor
organ shortage [2], but children still remain at an increased
risk of death on the waiting list for heart transplantation,
as a result of the rarity of small donor hearts in particular
[3]. Identifying all potential brain-dead donors and expand-
ing the donor pool on an international level is thus of vital
importance, especially for smaller countries like Switzer-
land. Experiences with these international exchange pro-
grammes have been published [4]. All these efforts have,
however, not resulted in a decrease in time on the waiting
list. As a result of the uncertainty and the time required
to obtain a donor heart, prolonged mechanical circulatory
support (MCS) has become mandatory to avoid death on
the waiting list (bridge to transplantation [BTT]).
Ventricular assist devices (VADs) have evolved owing to
the invention of advanced biocompatible materials, ver-
satile technologies and improved patient management al-
gorithms, and are now widely accepted in adult practice [5,
6]. However, their use in children is still limited for sever-
al reasons. Firstly, there is limited experience with paedi-
atric VADs, because in most major trials involving VADs
children have been excluded. In addition, there are differ-
ences between children and adults in the pathophysiology
of heart failure. Studies have been published which demon-
strate that congenital aetiology is associated with a signi-
ficantly higher postoperative mortality in paediatric VAD
patients [7, 8]. The substantial incidence of single vent-
ricles and Fontan circulations amongst paediatric patients
with end-stage heart failure poses a unique challenge for
paediatric MCS. This may lead to a less aggressive ap-
proach to initiating VADs in children in many institutions;
most centres have experience with extracorporeal mem-
brane oxygenation (ECMO), mainly for postcardiotomy
failure, as a bridge to recovery (BTR). ECMO has been the
mainstay for small children with heart or respiratory fail-
ure, with excellent outcomes for short-term support. Evid-
ence shows that after 2 to 3 weeks of support serious com-
plications such as bleeding occur [9], leading to an inferior
outcome compared with a shorter support time. A rate of
survival to hospital discharge of less than 50% with ECMO
support in children has been reported, as well as a reduction
of waiting list mortality from 38% on ECMO to 13% with
VAD use [10]. Another point to consider is that ECMO use
leads to immobilisation of the patient and the patient must
remain on the intensive care unit (ICU). Therefore VAD
implantation should be considered if long-term support is
anticipated and mobilisation of the patient is intended.
Secondly, although a large variety of adult sized VADs
have proven to be safe for long-term support [6], only a
small number of VADs are available for patients with a
body surface area (BSA) of less than 1.2 m2 or weight less
than 20 kg [11]. Thirdly, whereas in adult patients the num-
ber of biventricular assist device (BVAD) implantations
is declining [5, 12], the incidence of biventricular failure
among children remains high, ranging from 29% to 43% [9,
11]. BVAD has been identified as independent risk factor
for mortality [11].
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Development of paediatric ventricular
assist devices
In 1967, DeBakey used a left atrial to axillary artery VAD
in a 16-year-old girl suffering from postcardiotomy failure
after mitral valve replacement [13]. During the following
decades, modifications of the original “heart-lung ma-
chine” such as ECMO or extracorporeal centrifugal pumps
[14], have been the principal form of cardiac support. As
newer indications requiring long-term circulatory support
evolved, together with longer waiting times for donor or-
gans, the need for long-term MCS became evident. In
1989, Frazier implanted a mechanical assist device in a
nine-year-old boy, who was successfully bridged to heart
transplantation with a Biomedicus (Medtronic, Eden Prair-
ie, MN) centrifugal pump; the support time was twelve
hours. In 1990, the first Berlin Heart Excor, an adult size
50-ml pump, was implanted in a nine-year-old child for 1
week with an uneventful postoperative period after heart
transplantation [15]. Two years later, in 1992, pumps sized
10 ml, 25 ml and 30 ml were devised, and the 10-ml pump
was implanted in a 12-month-old child [16]. Two years
later, the first Medos VAD (Medos Medizintechnik Gm-
bH, Stolberg, Germany) was implanted successfully as a
bridge to transplantation [17]. Availability of implantable
continuous-flow left ventricular assist devices (LVADs)
such as the Heart Mate II (Thoratec Corp., Pleasanton,
CA) led to implantation in intermediate-size children [18].
However, evidence showed that incidences of thromboem-
bolic and haemorrhagic neurological events in children
differed from those in adults [7, 19–20], and that patient
size, device selection and postimplant anticoagulation regi-
mens needed to be tailored, as paediatric patients are not
simply small adults.
Purpose of mechanical circulatory
support
Historically, MCS was developed for BTT; however, in pa-
tients with myocarditis, or after cardiotomy, where a re-
covery of ventricular function is expected, MCS for days
to weeks during the critical interval may be as necessary
as it is for BTT. If a fast recovery is expected, ECMO re-
mains the mainstay of support. If a contraindication for
HTx, such as pulmonary hypertension or a successfully
treated malignancy with a too short observational period
for HTx, is diagnosed, a concept known as bridge to trans-
plantability should be considered. For this indication, a
VAD designed for long-term support is necessary. Suc-
cessful HTx after VAD support in patients diagnosed with
fixed pulmonary hypertension [21–22], in children or teen-
agers with chemotherapy-induced cardiomyopathy (CMP),
and successful bridge to transplantability [23] or recovery
using long-term VADs have been published [24–26]; in
our own experience an eight-year-old child suffering from
anthracycline-induced CMP could be provided with an in-
tracoporeal VAD for bridge to transplantability (fig. 1).
Indications for mechanical circulatory
support
Patient selection and timing remain crucial factors for im-
proving outcomes in VAD recipients. Children who have
critical peripheral perfusion (i.e. metabolic acidosis, cardi-
ac index <2.0 l/m2/min, mixed venous oxygen saturation
<40%) despite inotropic support and early signs of renal,
hepatic or multiorgan failure, and for whom there are no
surgical options to correct any residual structural lesions
should be considered for MCS. If a fast recovery can be
expected, and in most cases of postcardiotomy failure,
ECMO support will be the first choice. For children suf-
fering from chronic cardiomyopathy or when a fast recov-
ery cannot be expected, VAD implantation should be evalu-
ated. There are only a few contraindications for MCS, such
as ongoing malignant neoplastic diseases with a very lim-
ited life expectancy. Further contraindications are advanced
multiorgan failure, complex congenital heart lesions in-
volving intracardiac shunts or irreversible pulmonary fail-
Figure 1
Eight-year old child provided with a Heartware HVAD (third-
generation continuous flow device) as a bridge to candidacy.
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ure, and severe extracardiac malformations such as chro-
mosomal and genetic syndromes with a poor quality-of-life
prognosis. It has to be kept in mind that if VAD implant-
ation is performed the child must be suitable for HTx if
weaning off VAD is not possible.
There is evidence that a decision in favour of earlier VAD
implantation results in a better outcome, especially in chil-
dren under 1 year of age [27].
In the our Department for Congenital Cardiovascular Sur-
gery at the Children’s Hospital Zurich, we try to differenti-
ate between acute and chronic heart failure; for children un-
der inotropic support without the possibility to wean them
off or in the case of a deterioration of clinical status, MCS
is evaluated. If there are no absolute contraindications,
MCS will be initiated; once again, if a fast recovery may be
expected (i.e. acute myocarditis or postcardiotomy failure)
ECMO will be used. In chronic heart failure, a VAD will be
implanted; on the basis of the BSA and the right ventricu-
lar (RV) function of the child either an intracoporeal VAD
(BSA >0.6 m2 and acceptable RV function) or an extracor-
poreal VAD (BSA <0.6 m2 or severe biventricular failure)
will be chosen.
Currently used assist devices available
for long-term support in children
Currently there are only two VADs designed for children
with a body surface area below 1.2 m2: the Medos HIA and
the Berlin Heart Excor.
Medos HIA
The Medos HIA (Medos Medizintechnik AG, Stolberg,
Germany) is a miniaturised, extracorporeal, pneumatically
driven system suitable for children and adults for left, right
or biventricular support. Support times of over 30 days
have been reported with good results, but this device does
not allow the patient to be discharged home [17, 28].
Figure 2
The Berlin Heart Excor is suitable for children of all sizes and with
biventricular failure.
Paracorporeal Berlin Heart
Most data are available for the Berlin Heart Excor system
(Berlin Heart AG, Berlin, Germany) (figs 2 and 3); it was
specifically designed for small children. It is a paracorpor-
eal, pulsatile, pneumatically driven VAD for univentricu-
lar or biventricular support. The system offers a range of
pumps with valves divided into a blood and air chamber
and silicone cannula, for every body size between 3 kg and
adult size. The pump consists of a translucent, semi-rigid
housing of polyurethane. In 1990, the system was first suc-
cessfully used in a 8-year-old child at the Berlin Heart In-
stitute, Germany [15]. The Berlin group gained great ex-
perience with the EXCOR even in neonates, and reported
18 patients less than 1 year of age supported by EXCOR
Figure 3
Schema of the BVAD Berlin Heart (blue arrows = venous blood
flow, red arrows = arterial blood flow). (Property of Julia Schrempf,
Graz, Austria.)
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(9 LVADs, 9 BVADs) with a survival rate of 70% [29].
Although the EXCOR paediatric VAD has been approved
in Europe and used since the 1990s, thanks to regulatory
hurdles experience in the USA was limited until the be-
ginning of 2000. Morales and colleagues reported the ini-
tial North American experience in 73 patients from 2000 to
2004; the majority of patients were suffering from dilated
cardiomyopathy (58%) or congenital heart disease (26%);
age ranged from 12 days to 17.8 years; the lowest patient
weight was 3 kilograms. Extracorporeal membrane oxy-
genation was used as a bridge to EXCOR in 22 patients
(30%); a LVAD was implanted in 57% and a BVAD in
43%. Overall mortality on the EXCOR was 23%. The au-
thors concluded that younger age and BVAD use were
significant risk factors for death while on the EXCOR
[11]. Recently Fraser et al. published the results of the US
investigational device exemption (IDE) multicentre trial,
which examined the safety and efficacy of the device [30].
The study group compared the EXCOR with a historical
ECMO group and found that survival rates were signific-
antly higher with the EXCOR. Serious adverse events, in-
cluding infection, stroke and bleeding, were reported, with
0.07 events per patient-day in the VAD group and with 0.08
events per patient-day in the ECMO group [9].
Thoratec Paracorporeal Ventricular Assist Device
Several VADs designed for adults have been adopted for
use in children. The Heartmate II has been used in teen-
agers between 12 and 18 years old in various institutions
[18]. The extracorporeal Thoratec VADs (Thoratec Corpor-
ation, Pleasanton, USA) can be implanted in adults and
children. Like the Excor, it is a pneumatically driven
pulsatile VAD available for patients with a body-surface
area down to 0.7 m2 [31]. In adults, 69% of Paracorporeal
Ventricular Assist Device (PVAD) patients were success-
fully supported to HTx or device explantation (ht-
tp://www.thoratec.com/vad-trials-outcomes/clinical-out-
comes/thoratec-pvad.aspx). When using the Thoratec TLC-
II portable drive for these patients, successful home dis-
charge was reported [32]. There are no major trials invest-
igating the safety and effectiveness of Thoratec VADs in
the paediatric population. Reinhartz and colleagues repor-
ted PVAD support for up to 120 days in a patient popula-
tion with a BSA <1.3 m2. In this study congenital heart dis-
ease was associated with increased mortality [33].
DeBakey VAD Child
The worldwide first clinically implanted axial flow pump
was the MicroMed DeBakey VAD [34]. This gained FDA
approval as DeBakey VAD Child (MicroMed Technology
Inc., Houston, TX) for children older than 5 years or a with
body surface area between 0.7 and 1.5 m2. The first suc-
cessful BTT after 56 days on support with the Debakey
VAD Child was in a 14-year-old boy [35]; further implant-
ations were reported, with the smallest child being 6 years
old [36]. Very aggressive anticoagulation was necessary to
prevent pump thrombosis in the DeBakey VAD Child [37].
Today the DeBakey VAD Child is known as the HeartAss-
ist 5 Paediatric VAD (fig. 4).
Recently an Italian physician team implanted a tiny,
11-gram implantable pump, invented by Dr. Jarvik and pre-
viously only tested on animals, in a 16-month-old baby,
keeping the baby alive for 13 days before a switch back




One of the newest devices is the Heartware HVAD
(HeartWare Inc., Framingham, MA, USA) (see fig. 1). It is
a third generation rotary blood pump with a magnetically
levitated rotor. It was initially designed for left ventricular
support [38], but owing to its small size is also used as im-
plantable BVAD [39]. Because of its size it is suitable for
children to support congenital or acquired systemic circu-
lation [40]. Miera et al. reported their experience in seven
patients, the youngest being 6 years of age, with a median
support time of 75 days and a 86% success rate of bridging
to HTx [41]. First use of this VAD in children in the USA
has already been reported also [42].
Total artificial heart
Alongside the paracorporeal VADs, total artificial hearts
(TAHs) have been developed for biventricular failure. In
contrast to adults, in whom the use of BVADs is declining
[5, 12], the need for BVADs in children remains high [9,
11]. When implanting a TAH, the native heart is completely
excised. The Cardiowest (SynCardia, Tucson, AZ, USA)
(fig. 5) was approval for BTT [43] but cannot be used in
small children owing to its size. Nevertheless it remains an
option for larger children; Leprince reported good results
in patients with a BSA below 1.7 m2 [44]. To date, world-
wide there are 21 Cardiowest implants in patients ran-
ging from 13 to 17 years of age (personal communication).
Besides the Cardiowest, the AbioCor artificial heart (Abio-
med, Danvers, MA, USA) has evolved as TAH and human
implants have been successfully used, including in a pae-
diatric patient (18 years) [45] (http://www.youtube.com/
watch?v=oixUVlf5h9U). Even if TAHs are not a valid op-
tion for small children, intracorporeal VAD implantation is
tried to achieve better quality of life.
Anticoagulation
Thromboembolic events in children supported with VAD
remain serious adverse events and differ from those in
adults [7, 19–20]. No standard anticoagulation protocol
has been developed so far and anticoagulation is tailored
to different types of VAD and individualised by different
centres. To achieve a balance between minimising throm-
boembolic events and causing bleeding complications, an
anticoagulation strategy involving the international norm-
alised ratio (INR), the thrombocyte aggregation test (TAT)
and thrombelastography (TEG) has been proposed. The
USA investigational device trial for the EXCOR agreed on
the Edmonton protocol, which proposes a three-drug regi-
men involving aspirin, persantine and enoxaparin or oral
anticoagulation [11]. In the immediate postoperative peri-
od, unfractionated heparin is given guided by activated par-
tial thromboplastin time (aPTT; target approximately 1.5
times the baseline) or anti-factor Xa. After removal of
invasive lines and drains, long-term anticoagulation with
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warfarin (target INR from 2.5 to 3.5 depending on device
type) and additional antiplatelet therapy can be started. An-
tiplatelet therapy including aspirin and persantine is mon-
itored with TAT and TEG, respectively.
Bridge to transplantation
Children supported by VAD and not showing signs of car-
diac recovery (see also below “Bridge to recovery”) while
on support will undergo paediatric HTx. Time on the HTx
waiting list is increasing in all European countries regard-
less of patient age. Within the last decade, VADs in adults
have evolved dramatically with the introduction of continu-
ous flow devices, and permanent support, also known as
destination therapy, has become real for many adults ow-
ing to the excellent 2- year survival rates on LVAD sup-
port [46]. Permanent support is still not a valid option in
children; nevertheless VAD support times are increasing.
Results of paediatric HTx are excellent [47–48], even after
VAD support [8, 49]. Jeewa et al. reported that survival
Figure 4
The HeartAssist 5 (MicroMed Technology Inc, Houston, TX)
formerly known as DeBakey Child, usable in children down to 5
years, is the only ventricular assist device measuring the actual
flow using a flow probe. (http://www.micromedcv.com/united_states/
heart-assist-5/small_and_light.html).
Figure 5
The Cardiowest is a Total Artificial Heart provided by Snycardia
(Tucson, AZ, USA). (http://www.syncardia.com/Medical-
Professionals/compare-to-bivads.html).
during the period from HTx to hospital discharge was bet-
ter after VAD support (92%) than with ECMO (80%) [8,
10].
Bridge to recovery
Some patients supported with long-term VAD show
marked improvement of ventricular function during MCS,
but only a small number of patients undergo device ex-
plantation. The process of myocardial recovery is still not
completely understood and is dependent on various factors,
including age, initial diagnosis, time from diagnosis to
VAD implantation, and pulsatile or continuous-flow VAD
[50]. The basic mechanism of myocardial recovery seems
to be the unloading of the left ventricle leading to molecu-
lar reverse remodelling, decreased neurohumonal and cy-
tokine activation, as well as normalisation of cytoskeletal
integrity, a reduction in the size of myocytes and a decrease
in the extracellular matrix [51, 52]. Additional pharmaco-
logical treatment with a selective β2-agonist such as clen-
buterol [53] or intraoperative application of stem cells may
enhance myocardial recovery. Protocols for long-term
device weaning and explantation have been developed for
adult patients [54–56]. During VAD support frequent echo-
cardiography studies examining the effects of unloading
on LV size, shape and contractility should be evaluated.
If the LV wall motion and diameters show improvement
so-called “pump-stop echocardiography” and if needed
“pump-stop heart catheterisation” (continuous LVAD:
blocking the outflow graft of the LVAD) may be carried out
[54]. Under sufficient anticoagulation (check before “pump
stop”!) and additional heparin bolus if possible VAD sup-
port is reduced and finally stopped for some minutes (3–5
minutes). Criteria for long-lasting myocardial recovery and
possible LVAD explantation have been reported: sinus
rhythm, absence of or trivial mitral regurgitation, left
ventricular ejection fraction (LVEF) >45% and left
ventricular end-diastolic diameter (LVEDD) <55 mm [57].
These “pump-stop” examinations may be repeated a few
times but involve in-hospital observation for three days
(one day prior to pump-stop, next day pump-stop, one fur-
ther day observation). In children, experience with explant-
ation after long-term VAD support is very limited.
Conclusion
In children of up to 0.7 m2 body surface area, the Berlin
Heart Excor paediatric ventricular assist device remains the
only VAD for long-term support. Improvements in the ex-
isting paediatric VADs, as well as technical developments
and miniaturisation leading to third-generation VADs, offer
new perspectives. Third-generation continuous flow
devices like the HVAD achieved excellent results even in
support times of over 365 days. As anticoagulation re-
gimens evolve, minimising thromboembolic events and
bleeding complications remains one of the core issues of a
paediatric VAD programme.
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Figures (large format)
Figure 1
Eight-year old child provided with a Heartware HVAD (third-generation continuous flow device) as a bridge to candidacy.
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Figure 2
The Berlin Heart Excor is suitable for children of all sizes and with biventricular failure.
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Figure 3
Schema of the BVAD Berlin Heart (blue arrows = venous blood flow, red arrows = arterial blood flow). (Property of Julia Schrempf, Graz,
Austria.)
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Figure 4
The HeartAssist 5 (MicroMed Technology Inc, Houston, TX) formerly known as DeBakey Child, usable in children down to 5 years, is the only
ventricular assist device measuring the actual flow using a flow probe. (http://www.micromedcv.com/united_states/heart-assist-5/
small_and_light.html).
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Figure 5
The Cardiowest is a Total Artificial Heart provided by Snycardia (Tucson, AZ, USA). (http://www.syncardia.com/Medical-Professionals/compare-
to-bivads.html).
Review article Swiss Med Wkly. 2013;143:w13804
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 12 of 12
